
Moonshots with Peter Diamandis
Leading Stem Cell Expert: Stem Cells 101 - The Future of Medicine w/ Robert Hariri | EP #147
Feb 4, 2025
Robert Hariri, CEO of Celularity, is a leading authority in regenerative medicine and stem cell therapy. He discusses the fascinating world of stem cells, emphasizing their vital role in health and healing. Hariri explains why stem cell treatments aren't widely available in the U.S. and highlights the incredible potential of placental-derived stem cells for tackling diseases and enhancing longevity. His insights into the aging process of stem cells and their future applications promise exciting advancements in personalized healthcare and regenerative medicine.
01:18:24
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The regulatory environment in the U.S. hinders access to stem cell therapies, pushing patients to seek treatment abroad due to FDA restrictions.
- Stem cells, derived from sources like the placenta, are crucial for tissue regeneration and repair, with significant implications for aging and health maintenance.
Deep dives
Regulatory Challenges in Stem Cell Research
The current regulatory landscape in the United States presents significant challenges for stem cell therapies, resulting in the need for Americans to seek treatments abroad. This situation stems from the conservative nature of the FDA and the rigorous process required for therapeutic approval, which has left the U.S. behind other countries regarding accessibility to stem cell treatments. Despite decades of experience with stem cells, including established practices like bone marrow transplantation, the regulatory hurdles prevent widespread therapy availability. The potential therapeutic benefits of stem cells are substantial, and there is a growing belief that the advantages outweigh the perceived risks of long-term safety.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.